Skandinaviska Enskilda Banken (SEB)
TEVA icon

Skandinaviska Enskilda Banken (SEB)’s Teva Pharmaceuticals TEVA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,001,902
Closed -$62.5M – 646
2025
Q4 		$62.5M Buy
2,001,902
+200,901
+11% +$4.95M 0.25% 76
2025
Q3 		$36.4M Buy
1,801,001
+53,100
+3% +$933K 0.15% 122
2025
Q2 		$29.3M Buy
1,747,901
+24,700
+1% +$399K 0.13% 135
2025
Q1 		$26.5M Buy
1,723,201
+290,827
+20% +$5.19M 0.13% 139
2024
Q4 		$32M Buy
1,432,374
+172,122
+14% +$3.13M 0.14% 125
2024
Q3 		$22.7M Sell
1,260,252
-16,400
-1% -$287K 0.1% 165
2024
Q2 		$20.7M Hold
1,276,652
– – 0.1% 170
2024
Q1 		$18M Buy
1,276,652
+1,052,552
+470% +$13.3M 0.09% 197
2023
Q4 		$2.34M Buy
224,100
+20,700
+10% +$193K 0.01% 551
2023
Q3 		$2.08M Hold
203,400
– – 0.01% 537
2023
Q2 		$1.53M Buy
203,400
+53,600
+36% +$435K 0.01% 614
2023
Q1 		$1.33M Hold
149,800
– – 0.01% 643
2022
Q4 		$1.37M Buy
149,800
+10,100
+7% +$88.1K 0.01% 621
2022
Q3 		$1.13M Sell
139,700
-42,954
-24% -$380K 0.01% 652
2022
Q2 		$1.37M Sell
182,654
-41,700
-19% -$363K 0.01% 651
2022
Q1 		$2.11M Sell
224,354
-17,748
-7% -$148K 0.01% 615
2021
Q4 		$1.91M Sell
242,102
-23,883
-9% -$216K 0.01% 656
2021
Q3 		$2.59M Buy
265,985
+42,122
+19% +$394K 0.01% 581
2021
Q2 		$2.22M Sell
223,863
-5,907
-3% -$62.5K 0.01% 638
2021
Q1 		$2.65M Buy
229,770
+6,555
+3% +$75.2K 0.02% 571
2020
Q4 		$2.15M Sell
223,215
-30,063
-12% -$288K 0.01% 629
2020
Q3 		$2.28M Buy
253,278
+2,198
+0.9% +$23.3K 0.02% 533
2020
Q2 		$3.1M Buy
251,080
+14,400
+6% +$163K 0.03% 445
2020
Q1 		$2.13M Buy
236,680
+4,350
+2% +$44.6K 0.02% 457
2019
Q4 		$2.28M Buy
232,330
+13,190
+6% +$118K 0.02% 528
2019
Q3 		$1.51M Sell
219,140
-15,780
-7% -$121K 0.01% 608
2019
Q2 		$2.17M Buy
234,920
+18,055
+8% +$218K 0.02% 490
2019
Q1 		$3.4M Sell
216,865
-8,100
-4% -$143K 0.03% 350
2018
Q4 		$3.47M Buy
224,965
+860
+0.4% +$17.6K 0.03% 344
2018
Q3 		$4.83M Buy
224,105
+9,380
+4% +$218K 0.04% 304
2018
Q2 		$5.22M Buy
214,725
+26,750
+14% +$546K 0.04% 268
2018
Q1 		$3.21M Buy
187,975
+7,785
+4% +$152K 0.03% 289
2017
Q4 		$3.42M Buy
180,190
+24,225
+16% +$364K 0.03% 343
2017
Q3 		$2.75M Buy
155,965
+65,740
+73% +$1.48M 0.02% 401
2017
Q2 		$3M Buy
90,225
+9,400
+12% +$291K 0.03% 386
2017
Q1 		$2.59M Sell
80,825
-73
-0.1% -$2.49K 0.03% 398
2016
Q4 		$2.93M Sell
80,898
-582,902
-88% -$23.3M 0.04% 312
2016
Q3 		$30.5M Sell
663,800
-39,175
-6% -$2.04M 0.33% 65
2016
Q2 		$35.3M Sell
702,975
-217,400
-24% -$11.6M 0.4% 55
2016
Q1 		$49.2M Sell
920,375
-61,800
-6% -$3.63M 0.55% 35
2015
Q4 		$64.5M Buy
+982,175
New +$60.7M 0.84% 24

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s TEVA Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 2,001,902 shares — an estimated $62.5M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in TEVA in Q4 2015 and held it in 41 quarters. The position peaked at $64.5M in Q4 2015. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 2,001,902 Teva Pharmaceuticals shares in Q1 2026, an estimated $62.5M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 41 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Teva Pharmaceuticals position peaked at $64.5M in Q4 2015.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.